Vedanta Biosciences Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 95
Employees
  • Latest Deal Type
  • Corporate
  • Latest Deal Amount
  • $25M
Latest Deal Amount
  • Investors
  • 22

Vedanta Biosciences General Information

Description

Developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access oral therapies to treat autoimmune and inflammatory diseases efficiently.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 19 Blackstone Street
  • Cambridge, MA 02139
  • United States
+1 (857) 000-0000

Vedanta Biosciences Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vedanta Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Corporate 12-Jan-2021 $25M 00000 Completed Clinical Trials - Phase 2
11. Grant 30-Sep-2020 000.00 00000 Completed Clinical Trials - Phase 2
10. Debt - General 16-Sep-2020 0000 00000 Completed Clinical Trials - Phase 2
9. Grant 05-Dec-2019 00.00 00000 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C2) 23-Sep-2019 000.00 00000 00000 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series C) 13-May-2019 000.00 000.00 00000 Completed Clinical Trials - Phase 2
6. Grant 10-Jul-2018 0000 Completed Clinical Trials - Phase 2
5. Grant 02-Nov-2017 00.00 0000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 06-Jun-2016 $50M $50M 00000 Completed Clinical Trials - Phase 2
3. Accelerator/Incubator 02-Feb-2015 Completed Startup
To view Vedanta Biosciences’s complete valuation and funding history, request access »

Vedanta Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series C 0,000,000 00.000000 000.00 000.00 00 000.00 00.000
Series B 2,305,948 $0.000100 $22.65 $22.65 1x $22.65 16.96%
Series A1 4,000,000 $0.000100 $1 $1 1x $1 29.42%
To view Vedanta Biosciences’s complete cap table history, request access »

Vedanta Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies in
Drug Discovery
Cambridge, MA
95 As of 2021
00000
000000000000 00000

00000000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut a
0000000000000
South San Francisco, CA
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00

00000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Ness Ziona, Israel
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vedanta Biosciences Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AvidBiotics Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
00000 Formerly VC-backed Ness Ziona, Israel 000 00000 00000000000 00000
00000 00000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
00000 (0000 000000 Formerly VC-backed Somerville, MA 000 00000 00000000 00000
000000 000000 Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 25 competitors. Get the full list »

Vedanta Biosciences Executive Team (20)

Name Title Board Seat Contact Info
Bernat Olle Ph.D Co-Founder, Chief Executive Officer & Board Member
Mark Mullikin Chief Financial Officer
Daniel Couto Chief Operating Officer
Maggie McGuigan Senior Director of Finance
Brett Finlay Ph.D Scientific Co-Founder & Advisor
You’re viewing 5 of 20 executive team members. Get the full list »

Vedanta Biosciences Board Members (14)

Name Representing Role Since
Atsushi Shiota Vedanta Biosciences Board Observer 000 0000
Bennett Shapiro MD PureTech Health Board Member 000 0000
Bernat Olle Ph.D Vedanta Biosciences Co-Founder, Chief Executive Officer & Board Member 000 0000
Bharatt Chowrira Ph.D PureTech Health Board Member 000 0000
Chris Chen Vedanta Biosciences Board Observer 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Vedanta Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vedanta Biosciences Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Pfizer Corporation Minority 000 0000 000000 0
Public Health Emergency Government 000 0000 000000 0
FC Capital Growth/Expansion Minority 000 0000 000000 0
Partners Investment Venture Capital Minority 000 0000 000000 0
QUAD Investment Management Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 22 investors. Get the full list »